-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
αGalCer-RBD
![{PARAM:[Name]}({[CAS]})](https://resource.bocsci.com/structure/galcer-rbd.gif)
| Category | SARS-CoV |
| Description | αGalCer-RBD is a self-adjuvanting lipoprotein conjugate. αGalCer-RBD induces potent immunity against SARS-CoV-2 and its variants of concern. αGalCer-RBD conjugate induces RBD-specific, cytokine-producing T cell development. αGalCer-RBD has great potential to be an effective COVID-19 vaccine candidate. α-Galactosylceramide (αGalCer) is a potent invariant natural killer T cell (iNKT) agonist. RBD: receptor-binding domain. |
Product Information
| Molecular Weight | 1119.6 |
| Molecular Formula | C60H118N4O14 |
| Boiling Point | 313.6°C at 760mmHg |
| Flash Point | 117.3°C |
| Purity | ≥98% (HPLC) |
| Density | 0.94g/cm3 |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| Index Of Refraction | 1.452 |
| In Vitro | The first time conjugates the iNKT cell agonist on the protein antigen, and the resulting αGalCer-RBD conjugate anchored on liposomes biomimicking the virus capsid structure remarkably enhances the protective immune response against SARS- CoV-2. |
| In Vivo | αGalCer-RBD enhances the immune efficacy of the adjuvant and produces significantly stronger humoral responses and cellular responses in mice. |
| PSA | 34.14000 |
| Target | SARS-CoV |